哮喘管理要SMART:单一维持和缓解疗法

IF 2.4 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Journal of the American Board of Family Medicine Pub Date : 2024-07-01 DOI:10.3122/jabfm.2023.230456R1
Alexander F Infante, Christina Wells, Julie Loza, Keia Hobbs, Jennie B Jarrett, Abigail T Elmes
{"title":"哮喘管理要SMART:单一维持和缓解疗法","authors":"Alexander F Infante, Christina Wells, Julie Loza, Keia Hobbs, Jennie B Jarrett, Abigail T Elmes","doi":"10.3122/jabfm.2023.230456R1","DOIUrl":null,"url":null,"abstract":"<p><p>Single maintenance and reliever therapy (SMART) is an asthma treatment approach that utilizes combined inhaled corticosteroids and long-acting β-agonists for maintenance and quick relief therapy. Despite the evidence for its benefits in asthma treatment and its adoption into American and international asthma guidelines and recommendations, SMART remains a practice of some debate. This article reviews the available evidence for SMART and offers guidance for its integration into comprehensive asthma management. Overall, short-acting β-agonist-only asthma therapy regimens should be avoided, regardless of condition severity (SOR A Recommendation). Family medicine clinicians should start SMART for patients requiring either GINA Step 3 or 4 therapy, especially if they have signs of poor adherence (SOR B Recommendation). Finally, use budesonide-formoterol over other inhaled corticosteroid/long-acting β-agonist combinations when implementing SMART (SOR B Recommendation).</p>","PeriodicalId":50018,"journal":{"name":"Journal of the American Board of Family Medicine","volume":"37 4","pages":"745-752"},"PeriodicalIF":2.4000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Be SMART About Asthma Management: Single Maintenance and Reliever Therapy.\",\"authors\":\"Alexander F Infante, Christina Wells, Julie Loza, Keia Hobbs, Jennie B Jarrett, Abigail T Elmes\",\"doi\":\"10.3122/jabfm.2023.230456R1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Single maintenance and reliever therapy (SMART) is an asthma treatment approach that utilizes combined inhaled corticosteroids and long-acting β-agonists for maintenance and quick relief therapy. Despite the evidence for its benefits in asthma treatment and its adoption into American and international asthma guidelines and recommendations, SMART remains a practice of some debate. This article reviews the available evidence for SMART and offers guidance for its integration into comprehensive asthma management. Overall, short-acting β-agonist-only asthma therapy regimens should be avoided, regardless of condition severity (SOR A Recommendation). Family medicine clinicians should start SMART for patients requiring either GINA Step 3 or 4 therapy, especially if they have signs of poor adherence (SOR B Recommendation). Finally, use budesonide-formoterol over other inhaled corticosteroid/long-acting β-agonist combinations when implementing SMART (SOR B Recommendation).</p>\",\"PeriodicalId\":50018,\"journal\":{\"name\":\"Journal of the American Board of Family Medicine\",\"volume\":\"37 4\",\"pages\":\"745-752\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2024-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the American Board of Family Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3122/jabfm.2023.230456R1\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the American Board of Family Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3122/jabfm.2023.230456R1","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

单一维持和缓解疗法(SMART)是一种哮喘治疗方法,它将吸入皮质类固醇和长效β-激动剂联合用于维持和快速缓解治疗。尽管有证据表明 SMART 有助于哮喘治疗,并且已被美国和国际哮喘指南和建议所采纳,但 SMART 仍是一种备受争议的治疗方法。本文回顾了 SMART 的现有证据,并为将其纳入哮喘综合管理提供指导。总体而言,无论病情严重程度如何,都应避免仅使用短效 β-激动剂的哮喘治疗方案(SOR A 建议)。对于需要接受 GINA 第 3 步或第 4 步治疗的患者,尤其是有依从性差迹象的患者,家庭医疗临床医生应启动 SMART(SOR B 建议)。最后,在实施 SMART 时,应使用布地奈德-福莫特罗,而不是其他吸入式皮质类固醇/长效 β-受体激动剂组合(推荐意见 B)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Be SMART About Asthma Management: Single Maintenance and Reliever Therapy.

Single maintenance and reliever therapy (SMART) is an asthma treatment approach that utilizes combined inhaled corticosteroids and long-acting β-agonists for maintenance and quick relief therapy. Despite the evidence for its benefits in asthma treatment and its adoption into American and international asthma guidelines and recommendations, SMART remains a practice of some debate. This article reviews the available evidence for SMART and offers guidance for its integration into comprehensive asthma management. Overall, short-acting β-agonist-only asthma therapy regimens should be avoided, regardless of condition severity (SOR A Recommendation). Family medicine clinicians should start SMART for patients requiring either GINA Step 3 or 4 therapy, especially if they have signs of poor adherence (SOR B Recommendation). Finally, use budesonide-formoterol over other inhaled corticosteroid/long-acting β-agonist combinations when implementing SMART (SOR B Recommendation).

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.90
自引率
6.90%
发文量
168
审稿时长
4-8 weeks
期刊介绍: Published since 1988, the Journal of the American Board of Family Medicine ( JABFM ) is the official peer-reviewed journal of the American Board of Family Medicine (ABFM). Believing that the public and scientific communities are best served by open access to information, JABFM makes its articles available free of charge and without registration at www.jabfm.org. JABFM is indexed by Medline, Index Medicus, and other services.
期刊最新文献
Answering the "100 Most Important Family Medicine Research Questions" from the 1985 Hames Consortium. CERA: A Vehicle for Facilitating Research in Family Medicine. Current and Future Challenges to Publishing Family Medicine Research. Diversity in Family Medicine Research. Leveraging the All of Us Database for Primary Care Research with Large Datasets.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1